TY - JOUR
T1 - 5-Azacitidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia
T2 - A cancer and leukemia group B pilot study
AU - Peterson, B. A.
AU - Bloomfield, C. D.
AU - Gottlieb, A. J.
PY - 1982
Y1 - 1982
N2 - Twenty-nine adults with advanced acute nonlymphocyte leukemia were treated with an intensive chemotherapy program consisting of 5-azacitidine and zorubicin. Overall, eight patients (28%) achieved a complete remission. Although only one of 19 patients with refractory leukemia responded, seven of ten patients who were treated immediately following relapse from a prior remission achieved another complete remission. The duration of remission ranged from 5 to 33 weeks (median, 14). Treatment resulted in severe toxic reactions including myelosuppression, renal tubular dysfunction, and elevations in liver enzymes. In addition, each of the 15 patients who died of treatment- associated complications had a severe infection. This combination of 5-azacitidine and zorubicin is relatively ineffective for truly refractory leukemia, but it may be a useful alternative following relapse.
AB - Twenty-nine adults with advanced acute nonlymphocyte leukemia were treated with an intensive chemotherapy program consisting of 5-azacitidine and zorubicin. Overall, eight patients (28%) achieved a complete remission. Although only one of 19 patients with refractory leukemia responded, seven of ten patients who were treated immediately following relapse from a prior remission achieved another complete remission. The duration of remission ranged from 5 to 33 weeks (median, 14). Treatment resulted in severe toxic reactions including myelosuppression, renal tubular dysfunction, and elevations in liver enzymes. In addition, each of the 15 patients who died of treatment- associated complications had a severe infection. This combination of 5-azacitidine and zorubicin is relatively ineffective for truly refractory leukemia, but it may be a useful alternative following relapse.
UR - http://www.scopus.com/inward/record.url?scp=0020001928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020001928&partnerID=8YFLogxK
M3 - Article
C2 - 6174230
AN - SCOPUS:0020001928
SN - 0361-5960
VL - 66
SP - 563
EP - 566
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
IS - 3
ER -